The new Pergoveris® Pen by Haselmeier has received a positive assessment by Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).
Developed for its customer Merck, the Pergoveris® pen represents a further innovative self-injection system from Haselmeier for treating women who want to conceive. This adds to the company’s other pre-filled, ready-to-use pen injection aids.
The advantages of the new pen, which is available in three dosage strengths of 300 international units (IU), 450IU and 900IU, include a significantly improved ease of operation, and it now offers patients the highest level of safety in administering drugs, which can be correctly mixed with the right dosage.
In addition, doctors can now respond even better to the particular needs of their patients as the dosage can be adjusted in steps of 12.5IU during treatment.
Deputy development manager at Haselmeier Dr. Sascha Pohl said: "This is an important step for Merck and Haselmeier, which we can both be proud of. We are enabling our customer Merck to maintain its Family of Pens™ series on the market with a worthy successor.
"This generation of pens has again succeeded in exceeding patients’ needs. It is a nice feeling to be able to make your own contribution through your commitment to project planning."
Haselmeier sees itself as a strategic partner to pharmaceutical and biotechnological companies for the development and production of innovative application aids, which are intended to bring relief to patients’ lives and improve their quality of life across the board.